The uremic solute p-cresol decreases leukocyte transendothelial migration in vitro

International Immunology

Volumn 18, Issue 10, 2006, Pages 1453-1459

  Faure, Valérie ^a   Cerini, Claire ^a   Paul, Pascale ^a   Berland, Yvon ^b   Dignat George, Françoise ^a   Brunet, Philippe ^a,b  

^a INSERM   (France)

^b HÔPITAL DE LA CONCEPTION   (France)

Author keywords

Chronic renal failure; Endothelium; Immunodeficiency; Transmigration; Uremic solutes

Indexed keywords

ALBUMIN; CELL ADHESION MOLECULE; CHEMOKINE; FRACTALKINE; INTERLEUKIN 1BETA; INTERLEUKIN 8; JUNCTIONAL ADHESION MOLECULE A; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PARA CRESOL; UNCLASSIFIED DRUG;

ALBUMIN BLOOD LEVEL; ARTICLE; CELL VIABILITY; CHRONIC KIDNEY FAILURE; COMPARTMENT MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENDOTHELIUM CELL; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IN VITRO STUDY; LEUKOCYTE MIGRATION; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SOLUTE; UMBILICAL VEIN; UREMIA;

CELLS, CULTURED; CHEMOTAXIS, LEUKOCYTE; CRESOLS; CYTOKINES; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; KIDNEY FAILURE, CHRONIC; LEUKOCYTES; RNA, MESSENGER; UREMIA;

EID: 33749009003     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxl077     Document Type: Article

References (45)

1. Port, F. K. 1990. Mortality and causes of death in patients with end-stage renal failure. Am. J. Kidney Dis. 15:215.
2. Vanholder, R. and Van Biesen, W. 2002. Incidence of infectious morbidity and mortality in dialysis patients. Blood Purif. 20:477.
3. Cohen, G., Haag-Weber, M. and Horl, W. H. 1997. Immune dysfunction in uremia. Kidney Int. Suppl. 62:S79.
4. Pesanti, E. L. 2001. Immunologic defects and vaccination in patients with chronic renal failure. Infect. Dis. Clin. North Am. 15:813.
5. Vanholder, R., Ringoir, S., Dhondt, A. et al. 1991. Phagocytosis in uremic and hemodialysis patients: A prospective and cross sectional study. Kidney Int. 39:320.
6. Haag-Weber, M. and Horl, W. H. 1996. Dysfunction of polymorphonuclear leukocytes in uremia. Semin. Nephrol. 16:192.
7. Lindner, A., Vanholder, R., De Smet, R. et al. 1997. HPLC fractions of human uremic plasma inhibit the RBC membrane calcium pump. Kidney Int. 51:1042.
8. Glorieux, G., Hsu, C., De Smet, R. et al. 2001. The anti-proliferative effect of calcitriol on HL-60 cells is neutralized by uraemic biological fluids. Nephrol. Dial. Transplant. 16:246.
9. Vanholder, R., De Smet, R., Waterloos, M. A. et al. 1995. Mechanisms of uremic inhibition of phagocyte reactive species production: characterization of the role of p-cresol. Kidney Int. 47:510.
10. Wratten, M. L., Tetta, C., De Smet, R. et al. 1999. Uremic ultrafiltrate inhibits platelet-activating factor synthesis. Blood Purif. 17:134.
11. De Smet, R., Van Kaer, J., Van Vlem, B. et al. 2003. Toxicity of free p-cresol: A prospective and cross-sectional analysis. Clin. Chem. 49:470.
12. Carlos, T. M. and Harlan, J. M. 1994. Leukocyte-endothelial adhesion molecules. Blood 84:2068.
13. Muller, W. A. 2003. Leukocyte-endothelial-cell interactions in leukocyte transmigration and the inflammatory response. Trends Immunol. 24:327.
14. Adams, D. H. and Lloyd, A. R. 1997. Chemokines: Leukocyte recruitment and activation cytokines. Lancet 15:490.
15. Briones, M. A., Phillips, D. J., Renshaw, M. A. et al. 2001. Expression of chemokine by human coronary-artery and umbilical-vein endothelial cells and its regulation by inflammatory cytokines. Coron Artery Dis. 12:179.
16. Bazan, J. F., Bacon, K. B., Hardiman, G. et al. 1997. A new class of membrane-bound chemokine with a CX3C motif. Nature 385:640.
17. Fong, A. M., Robinson, L. A., Steeber, D. A. et al. 1998. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J. Exp. Med. 188:1413.
18. Imaizumi, T., Yoshida, H. and Satoh, K. 2004. Regulation of CX3CL1/ fractalkine expression in endothelial cells. J. Atheroscler. Thromb. 11:15.
19. Dou, L., Cerini, C., Brunet, P. et al. 2002. p-Cresol, a uremic toxin, decreases endothelial cell response to inflammatory cytokines. Kidney Int. 62:1999.
20. Jaffe, E. A., Nachman, R. L., Becker, C. G. et al. 1973. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J. Clin. Invest. 52:2745.
21. Vanholder, R., De Smet, R., Glorieux, G. et al. 2003. Review on uremic toxins: Classification, concentration, and interindividual variability. Kidney Int. 63:1934.
22. Sunder-Plassmann, G., Hofbauer, R., Sengoelge, G. and Horl, W. H. 1996. Quantification of leukocyte migration: Improvement of a method. Immunol. Invest. 25:49.
23. Chapuis, N., Bruhlmann, C., Reist, M. et al. 2001. The esterase-like activity of serum albumin may be due to cholinesterase contamination. Pharm. Res. 18:1435.
24. Esser, S., Lampugnani, M. G., Corada, M. et al. 1998. Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. J. Cell Sci. 111:1853.
25. Poncelet, P. and Carayon, P. 1985. Cytofluorometric quantification of cell-surface antigens by indirect immunofluorescence using monoclonal antibodies. J. Immunol. Methods 85:65.
26. Cullen, J. P., Sayeed, S., Jin, Y. et al. 2005. Ethanol inhibits monocyte chemotactic protein-1 expression in interleukin-1{beta}-activated human endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 289:1669.
27. Kuldo, J. M., Westra, J., Asgeirsdottir, S. A. et al. 2005. Differential effects of NF-{kappa}B and p38 MAPK inhibitors and combinations thereof on TNF-{alpha}- and IL-1{beta}-induced proinflammatory status of endothelial cells in vitro. Am. J. Physiol. Cell. Physiol. 289:1229.
28. Chapman, G. A., Moores, K. E., Gohil, J. et al. 2000. The role of fractalkine in the recruitment of monocytes to the endothelium. Eur. J. Pharmacol. 392:189.
29. Imai, T., Hieshima, K., Haskell, C. et al. 1997. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 91:521.
30. Goda, S., Imai, T., Yoshie, O. et al. 2000. CX3C-chemokine, fractalkine-enhanced adhesion of THP-1 cells to endothelial cells through integrin-dependent and -independent mechanisms. J. Immunol. 164:4313.
31. Yoneda, O., Imai, T., Goda, S. et al. 2000. Fractalkine-mediated endothelial cell injury by NK cells. J. Immunol. 164:4055.
32. Garton, K. J., Gough, P. J., Blobel, C. P. et al. 2001. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J. Biol. Chem. 276:37993.
33. Oak, M. H., El Bedoui, J., Anglard, P. et al. 2004. Red wine polyphenolic compounds strongly inhibit pro-matrix metalloproteinase-2 expression and its activation in response to thrombin via direct inhibition of membrane type 1-matrix metalloproteinase in vascular smooth muscle cells. Circulation 110:1861.
34. Oku, N., Matsukawa, M., Yamakawa, S. et al. 2003. Inhibitory effect of green tea polyphenols on membrane-type 1 matrix metalloproteinase, MT1-MMP. Biol. Pharm. Bull. 26:1235.
35. Kim, J. H., Shim, J. S., Lee, S. K. et al. 2002. Microarray-based analysis of anti-angiogenic activity of demethoxycurcumin on human umbilical vein endothelial cells: Crucial involvement of the down-regulation of matrix metalloproteinase. J Cancer Res. 93:1378.
36. Garcia, G. E., Xia, Y., Chen, S. et al. 2000. NF-kappaB-dependent fractalkine induction in rat aortic endothelial cells stimulated by IL1beta, TNF-alpha, and LPS. J. Leukoc. Biol. 67:577.
37. Denk, A., Goebeler, M., Schmid, S. et al. 2001. Activation of NF-kappa B via the (kappa B kinase complex is both essential and sufficient for proinflammatory gene expression in primary endothelial cells. J. Biol. Chem. 276:28451.
38. Goebeler, M., Gillitzer, R., Kilian, K. et al. 2001. Multiple signaling pathways regulate NF-kappaB-dependent transcription of the monocyte chemoattractant protein-1 gene in primary endothelial cells. Blood 97:46.
39. Li, X. and Stark, G. R. 2002. NFkappaB-dependent signaling pathways. Exp. Hematol. 30:285.
40. Thylen, P., Fernvik, E., Haegerstrand, A. et al. 1997. Dialysis-induced serum factors inhibit adherence of monocytes and granulocytes to adult human endothelial cells. Am. J. Kidney Dis. 29:78.
41. Hida, M., Aiba, Y., Sawamura, S. et al. 1996. Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis. Nephron 74:349.
42. De Smet, R., David, F., Sandra, P. et al. 1998. A sensitive HPLC method for the quantification of free and total p-cresol in patients with chronic renal failure. Clin. Chim Acta 278:1.
43. Lesaffer, G., De Smet, R., Lameire, N. et al. 2000. Intradialytic removal of protein-bound uraemic toxins: Role of solute characteristics and of dialyser membrane. Nephrol. Dial. Transplan. 15:50.
44. De Loor, H., Bammens, B., Evenepoel, P. et al. 2005. Gas chromatographic-mass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uremic and normal serum. Clin Chem. 51:1535.
45. Bammens, B., Evenepoel, P., Keuleers, H. et al. 2006. Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney Int. 69:1081.